Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
Status:
Unknown status
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the 6-month Progression free survival
(PFS) when intravenous (IV) AR-67 is administered in adults with confirmed recurrence of GBM
who have not recently (> 90 days) recurred after treatment bevacizumab (including patients
who've received temazolamide, but no bevacizumab). The primary objective in the rapid
bevacizumab failure group (< 90 days) is to determine the 2-month PFS.